CO2018004473A2 - Compuestos agonistas de ppar y composiciones farmaceuticas - Google Patents
Compuestos agonistas de ppar y composiciones farmaceuticasInfo
- Publication number
- CO2018004473A2 CO2018004473A2 CONC2018/0004473A CO2018004473A CO2018004473A2 CO 2018004473 A2 CO2018004473 A2 CO 2018004473A2 CO 2018004473 A CO2018004473 A CO 2018004473A CO 2018004473 A2 CO2018004473 A2 CO 2018004473A2
- Authority
- CO
- Colombia
- Prior art keywords
- ppar
- diseases
- pharmaceutical compositions
- agonist compounds
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 101150014691 PPARA gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 108010015181 PPAR delta Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562238629P | 2015-10-07 | 2015-10-07 | |
| US201562243263P | 2015-10-19 | 2015-10-19 | |
| US201662352348P | 2016-06-20 | 2016-06-20 | |
| PCT/US2016/055521 WO2017062468A1 (en) | 2015-10-07 | 2016-10-05 | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2018004473A2 true CO2018004473A2 (es) | 2018-09-20 |
Family
ID=57200096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2018/0004473A CO2018004473A2 (es) | 2015-10-07 | 2016-10-05 | Compuestos agonistas de ppar y composiciones farmaceuticas |
Country Status (26)
| Country | Link |
|---|---|
| US (6) | US10399958B2 (enExample) |
| EP (3) | EP3770146B1 (enExample) |
| JP (2) | JP6657413B2 (enExample) |
| KR (2) | KR102667386B1 (enExample) |
| CN (3) | CN113004205B (enExample) |
| AU (3) | AU2016333963C1 (enExample) |
| BR (1) | BR112018006866B1 (enExample) |
| CA (1) | CA3000431A1 (enExample) |
| CO (1) | CO2018004473A2 (enExample) |
| DK (1) | DK3359528T3 (enExample) |
| EA (1) | EA037371B1 (enExample) |
| ES (3) | ES2949852T3 (enExample) |
| HU (1) | HUE058154T2 (enExample) |
| IL (3) | IL258225B (enExample) |
| JO (3) | JO3738B1 (enExample) |
| MA (2) | MA52648A (enExample) |
| MX (3) | MX392524B (enExample) |
| MY (1) | MY203081A (enExample) |
| PH (1) | PH12018500762A1 (enExample) |
| PL (1) | PL3359528T3 (enExample) |
| PT (1) | PT3359528T (enExample) |
| SG (1) | SG10201906400SA (enExample) |
| TW (3) | TWI742479B (enExample) |
| UA (1) | UA122237C2 (enExample) |
| WO (1) | WO2017062468A1 (enExample) |
| ZA (4) | ZA201802029B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912681B2 (en) | 2016-10-05 | 2024-02-27 | Mitobridge, Inc. | Crystalline and salt forms of PPAR agonist compounds |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037371B1 (ru) * | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| ES2859487T3 (es) * | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| US20220331267A1 (en) * | 2019-09-05 | 2022-10-20 | Rush University Medical Center | Methods and compositions for treatment of demyelinating disorders |
| US11634387B2 (en) | 2019-09-26 | 2023-04-25 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| WO2022189856A1 (en) | 2021-03-08 | 2022-09-15 | Abionyx Pharma Sa | Compounds useful for treating liver diseases |
| MX2023010537A (es) * | 2021-03-08 | 2023-11-28 | Abionyx Pharma Sa | Compuestos útiles para tratar enfermedades del hígado. |
| BR112023025221A2 (pt) | 2021-06-02 | 2024-02-27 | Astellas Pharma Inc | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
| WO2025207099A1 (en) | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4228281A (en) | 1977-09-23 | 1980-10-14 | Ciba-Geigy Corporation | Dicarboxylic acids containing triazine rings |
| DE4123341A1 (de) | 1991-07-15 | 1993-01-21 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| GB9511694D0 (en) | 1995-06-09 | 1995-08-02 | Fujisawa Pharmaceutical Co | Benzamide derivatives |
| NZ514453A (en) | 1999-02-26 | 2003-04-29 | Merck & Co Inc | Novel sulfonamide compounds and uses thereof |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| ATE447557T1 (de) | 2000-08-17 | 2009-11-15 | Pfizer Ltd | Substitutuierte imidazole als tafia inhibitoren |
| CN100457730C (zh) * | 2002-08-29 | 2009-02-04 | 默克公司 | 具有抗糖尿病活性的吲哚化合物 |
| US7820682B2 (en) | 2002-10-03 | 2010-10-26 | Ono Pharmaceutical Co., Ltd. | LPA receptor antagonist |
| WO2004060367A1 (en) | 2002-12-30 | 2004-07-22 | Fujisawa Pharmaceutical Co., Ltd. | Imidazole and triazole derivatives useful as selective cox-1 inhibitors |
| MXPA06003357A (es) | 2003-09-26 | 2006-06-08 | Japan Tobacco Inc | Metodo para inhibir la produccion de lipoproteina remanente. |
| BRPI0515140A (pt) | 2004-09-06 | 2008-07-08 | Hoffmann La Roche | derivados de benzamidina de 4-aminometila e seu emprego como inibidores do fator viia |
| CA2597148A1 (en) | 2005-02-15 | 2007-03-15 | F. Hoffmann-La Roche Ag | Amide derivatives as ppar activators |
| BRPI0615948A2 (pt) | 2005-09-07 | 2011-05-31 | Plexxikon Inc | composto ativo de ppar, sua composição, seu kit e seu uso |
| NZ569329A (en) | 2006-01-30 | 2011-09-30 | Transtech Pharma Inc | Substituted imidazole derivatives and their use as PTPase inhibitors |
| MX2008012404A (es) | 2006-03-28 | 2008-10-09 | Novartis Ag | Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g. |
| CN101466687B (zh) | 2006-04-18 | 2012-04-11 | 日本化学医药株式会社 | 过氧化物酶体增殖剂激活受体δ的激活剂 |
| DE102006023336A1 (de) | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| CN101085772A (zh) | 2006-06-07 | 2007-12-12 | 上海艾力斯医药科技有限公司 | 一类具有PPARγ激动剂活性的化合物及其应用 |
| EP2128138A1 (en) | 2007-01-29 | 2009-12-02 | Takeda Pharmaceutical Company Limited | Pyrazole compound |
| KR20080082541A (ko) | 2007-03-07 | 2008-09-11 | 동아제약주식회사 | 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도 |
| JP2008285452A (ja) | 2007-05-21 | 2008-11-27 | Ono Pharmaceut Co Ltd | ＰＰＡＲα／γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬 |
| CA2710764A1 (en) | 2007-12-28 | 2009-07-09 | The Salk Institute For Biological Studies | Methods for enhancing muscle performance and tone |
| JP5895104B2 (ja) | 2012-08-28 | 2016-03-30 | コチ・ウニヴェルシテシＫｏｃ Ｕｎｉｖｅｒｓｉｔｅｓｉ | 骨板 |
| EP2981522A4 (en) | 2013-04-05 | 2016-08-31 | Salk Inst For Biological Studi | PPAR AGONISTS |
| WO2015035171A1 (en) | 2013-09-09 | 2015-03-12 | High Point Pharmaceuticals, Llc | Use of a ppar-delta agonist for treating muscle atrophy |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| US20170305894A1 (en) | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EA037371B1 (ru) | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| ES2887008T3 (es) * | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
| ES2859487T3 (es) | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| SMT202100321T1 (it) * | 2016-12-30 | 2021-07-12 | Mitobridge Inc | Inibitori della poli-adp ribosio polimerasi (parp) |
-
2016
- 2016-10-05 EA EA201890776A patent/EA037371B1/ru unknown
- 2016-10-05 WO PCT/US2016/055521 patent/WO2017062468A1/en not_active Ceased
- 2016-10-05 KR KR1020217032197A patent/KR102667386B1/ko active Active
- 2016-10-05 BR BR112018006866-7A patent/BR112018006866B1/pt active IP Right Grant
- 2016-10-05 HU HUE16785611A patent/HUE058154T2/hu unknown
- 2016-10-05 MX MX2020011099A patent/MX392524B/es unknown
- 2016-10-05 SG SG10201906400SA patent/SG10201906400SA/en unknown
- 2016-10-05 EP EP20193960.0A patent/EP3770146B1/en active Active
- 2016-10-05 MA MA052648A patent/MA52648A/fr unknown
- 2016-10-05 PT PT167856111T patent/PT3359528T/pt unknown
- 2016-10-05 ES ES20193962T patent/ES2949852T3/es active Active
- 2016-10-05 ES ES20193960T patent/ES2988059T3/es active Active
- 2016-10-05 CN CN202110284826.5A patent/CN113004205B/zh active Active
- 2016-10-05 CO CONC2018/0004473A patent/CO2018004473A2/es unknown
- 2016-10-05 KR KR1020187012860A patent/KR102667385B1/ko active Active
- 2016-10-05 EP EP20193962.6A patent/EP3795566B1/en active Active
- 2016-10-05 UA UAA201802841A patent/UA122237C2/uk unknown
- 2016-10-05 CA CA3000431A patent/CA3000431A1/en active Pending
- 2016-10-05 PL PL16785611T patent/PL3359528T3/pl unknown
- 2016-10-05 JP JP2018538052A patent/JP6657413B2/ja active Active
- 2016-10-05 MY MYPI2018000444A patent/MY203081A/en unknown
- 2016-10-05 AU AU2016333963A patent/AU2016333963C1/en active Active
- 2016-10-05 EP EP16785611.1A patent/EP3359528B1/en active Active
- 2016-10-05 ES ES16785611T patent/ES2906379T3/es active Active
- 2016-10-05 CN CN202110286947.3A patent/CN113024467B/zh active Active
- 2016-10-05 MX MX2018004295A patent/MX380281B/es unknown
- 2016-10-05 US US15/766,455 patent/US10399958B2/en active Active
- 2016-10-05 MX MX2020011100A patent/MX392523B/es unknown
- 2016-10-05 DK DK16785611.1T patent/DK3359528T3/da active
- 2016-10-05 MA MA052098A patent/MA52098A/fr unknown
- 2016-10-05 CN CN201680057879.0A patent/CN108349904B/zh active Active
- 2016-10-06 JO JOP/2016/0217A patent/JO3738B1/ar active
- 2016-10-07 TW TW108144723A patent/TWI742479B/zh active
- 2016-10-07 TW TW108133069A patent/TWI730408B/zh active
- 2016-10-07 TW TW105132668A patent/TWI730006B/zh active
-
2018
- 2018-03-19 IL IL258225A patent/IL258225B/en unknown
- 2018-03-27 ZA ZA2018/02029A patent/ZA201802029B/en unknown
- 2018-04-06 PH PH12018500762A patent/PH12018500762A1/en unknown
-
2019
- 2019-07-15 US US16/510,976 patent/US10479775B1/en active Active
- 2019-11-13 US US16/682,676 patent/US10906885B2/en active Active
- 2019-12-18 AU AU2019283837A patent/AU2019283837B2/en active Active
-
2020
- 2020-02-03 JP JP2020016147A patent/JP6866514B2/ja active Active
- 2020-06-15 IL IL275387A patent/IL275387B/en unknown
- 2020-06-15 IL IL275392A patent/IL275392B/en unknown
- 2020-06-18 ZA ZA2020/03662A patent/ZA202003662B/en unknown
- 2020-06-18 ZA ZA2020/03663A patent/ZA202003663B/en unknown
- 2020-06-18 ZA ZA2020/03664A patent/ZA202003664B/en unknown
- 2020-09-14 JO JOJO/P/2020/0231A patent/JOP20200231B1/ar active
- 2020-09-14 JO JOJO/P/2020/0230A patent/JOP20200230B1/ar active
- 2020-12-02 AU AU2020281069A patent/AU2020281069B2/en active Active
-
2021
- 2021-01-29 US US17/162,157 patent/US11578052B2/en active Active
-
2023
- 2023-02-13 US US18/108,785 patent/US20230373948A1/en not_active Abandoned
-
2024
- 2024-01-25 US US18/422,793 patent/US20240417383A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11912681B2 (en) | 2016-10-05 | 2024-02-27 | Mitobridge, Inc. | Crystalline and salt forms of PPAR agonist compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018004473A2 (es) | Compuestos agonistas de ppar y composiciones farmaceuticas | |
| CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CL2014002541A1 (es) | Compuestos derivados de imidazol fusionado con heterociclos, como inhibidores de diacilglicerol aciltransferasa 2; composicion farmaceutica que los comprende, util para el tratamiento de diabetes tipo i y ii, enfermedad cardiaca coronaria, artritis, trombosis, alzheimer, entre otras enfermedades. | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| GT201800020A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| GT201600147A (es) | Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2 | |
| EA201890052A1 (ru) | Регуляторы nrf2 | |
| MX2017014375A (es) | Moduladores del ccr2. | |
| MX381313B (es) | Derivados de benzimidazol como moduladores de ror-gamma | |
| CU20170015A7 (es) | Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA201690629A1 (ru) | Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip | |
| CO2018005639A2 (es) | Sililfenoxiheterociclos trisustituidos y análogos | |
| ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| EA201600589A1 (ru) | Ингибиторы диацилглицеринацилтрансферазы 2 для применения в лечении метаболических и связанных с метаболизмом расстройств | |
| ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
| MX373549B (es) | Derivado de pirazol amida. | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| CO2019012767A2 (es) | Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo | |
| ECSP14030779A (es) | Inhibidores del nampt | |
| MX2017001553A (es) | Derivados de heterociclico opcionalmente condensados de pirimidina utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias. |